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a  b  s  t  r  a  c  t
The  Galleria  mellonella  infection  model  was used  to assess  the  in  vivo  efﬁcacy  of phage  therapy  against
laboratory  and clinical  strains  of  Pseudomonas  aeruginosa.  In a  ﬁrst  series  of  experiments,  Galleria  were
infected  with  the  laboratory  strain  P.  aeruginosa  PAO1  and  were  treated  with  varying  multiplicity  of infec-
tion  (MOI)  of  phages  either  2 h  post-infection  (treatment)  or  2 h pre-infection  (prevention)  via injection
into  the  haemolymph.  To  address  the  kinetics  of  infection,  larvae  were  bled  over a period  of 24  h  for
quantiﬁcation  of  bacteria  and phages.  Survival  rates  at  24 h  when  infected  with  10 cells/larvae  were
greater  in the  prevention  versus  treatment  model  (47%  vs.  40%,  MOI =  10;  47% vs. 20%,  MOI  = 1; and  33%
vs.  7%,  MOI =  0.1).  This  pattern  held  true  when  100  cells/larvae  were  used  (87%  vs. 20%, MOI =  10;  53%
vs.  13%,  MOI  =  1; 67%  vs. 7%,  MOI  = 0.1).  By 24  h post-infection,  phages  kept  bacterial  cell  numbers  in  the
haemolymph  1000-fold  lower  than  in the  non-treated  group.  In  a  second  series  of  experiments  using
clinical  strains  to further  validate  the  prevention  model,  phages  protected  Galleria  when infected  with
both  a bacteraemia  (0% vs. 85%)  and  a cystic  ﬁbrosis  (80%  vs.  100%)  isolate.  Therefore,  this  study  validates
the  use  of  G. mellonella  as a  simple,  robust  and  cost-effective  model  for  initial  in  vivo examination  of  P.
aeruginosa-targeted  phage  therapy,  which  may  be  applied  to other  pathogens  with  similarly  low  infective
doses.
Crown  Copyright  © 2015  Published  by Elsevier  B.V.  All  rights  reserved.. Introduction
Multidrug-resistant bacterial pathogens pose an ever-
ncreasing threat to human health. This problem is in part
ue to a lack of novel antibiotics approved for use over the last
ew decades, resulting in an urgent need to identify new avenues
or treating bacterial infections, especially those caused by Gram-
egative pathogens [1]. Pseudomonas aeruginosa is an opportunistic
athogen that is a leading cause of infection among burn victims
nd patients with cystic ﬁbrosis (CF). It is also responsible for a
arge number of healthcare-associated infections. To make matters
orse, P. aeruginosa is associated with hypermutability and, due to
igh antibiotic selective pressure, has given rise to the emergence
f multidrug-resistant strains in the population; thus, concerns
bout available effective treatments are growing [2,3]. In the
∗ Corresponding author. Tel.: +44 29 2020 5557.
E-mail address: mbeeton@cardiffmet.ac.uk (M.L. Beeton).
1 The two  authors contributed equally to this article.
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.04.005
924-8579/Crown Copyright © 2015 Published by Elsevier B.V. All rights reserved.UK, resistance to two or more antibiotics among P. aeruginosa
isolated from the lungs of CF patients has risen to 40% [4]. This is a
worrying statistic as colonisation of the CF lung with P. aeruginosa
is a predictor of poor prognosis and is associated with a two- to
three-fold increased risk of death over an 8-year period [5]. For
this reason, novel anti-infectives are needed.
Facing such a scenario, interest in phage therapy in Western
society has experienced a resurgence after research into this area
fell out of favour following the discovery of antibiotics. Bacterio-
phages (or phages) are viral particles able to infect bacterial cells
with high speciﬁcity, taking over cellular function to replicate their
genomes. Upon maturation, the bacterial cell wall is lysed to release
viral progeny.
Phage therapy can be broadly subdivided into four main cate-
gories [6]: (i) conventional phage therapy using mainly lytic phages
to lyse target bacterial species; (ii) modiﬁed phage therapy using
genetically altered phages with favourable properties, such as non-
lytic replication to avoid the possibility of endotoxic shock when
bacterial cells are lysed; (iii) treatment with enzymes derived
from phages, such as administration of endolysins to selectively
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egrade the bacterial peptidoglycan cell wall; and (iv) the con-
ept of combination therapy with phages and antibiotics, where
hages exhibit properties to degrade polysaccharide components
f bioﬁlms therefore allowing antibiotics to penetrate and elicit an
ction [7].
Although in vitro systems allow for a reductionist approach to
xamining phage interactions with target bacteria, they do not take
nto account a more complex in vivo system. Mammalian mod-
ls are an excellent means of testing phage therapy but require
thical approval, signiﬁcant infrastructure and funds. The Galleria
ellonella model ﬁlls the void between these two systems, pro-
iding a cheap, reliable and ethics-free system for testing novel
ntimicrobials [8]. Here we describe the ﬁrst use of the G. mellonella
odel to evaluate the efﬁcacy of phage therapy both for treatment
nd prophylaxis of P. aeruginosa infection.
. Materials and methods
.1. Bacterial strains and preparation of inoculum
Phage therapy was assessed using P. aeruginosa PAO1 and
wo low-passage clinical isolates (PA45291 and BC09007) iso-
ated from bacteraemia and CF samples, respectively. Bacteria were
rown to mid-log phase in Luria–Bertani (LB) broth (Sigma-Aldrich,
orset, UK) and were washed once in phosphate-buffered saline
PBS). Cells were re-suspended in PBS to a ﬁnal concentration of
 × 108 CFU/mL and were diluted accordingly in PBS to the required
noculum size for each experiment.
.2. Phage cocktail preparation and titration
All six distinct phages were propagated on P. aeruginosa PAO1
train and were combined to establish a cocktail suspension. The
enomic sequence of the six phages can be found in the National
enter for Biotechnology Information (NCBI) GenBank database
nder accession nos. KR054028–KR054033, with a full descrip-
ion of the phages detailed elsewhere (submitted). Brieﬂy, 100 L
f phage lysate and 100 L of host growing culture were mixed
nd left for 5 min  at room temperature. Following incubation, 3 mL
f LB soft agar (Sigma-Aldrich) containing 0.65% bacteriological
gar (Sigma-Aldrich)was added and poured onto agar plates. Fol-
owing overnight incubation at 37 ◦C, plates displaying conﬂuent
ysis were selected and 3 mL  of SM buffer [5 M NaCl, 1 M MgSO4,
 M Tris–HCl (pH 7.5), 0.01% w/v gelatine] and 2% (v/v) chloro-
orm (Sigma-Aldrich)were added before incubation at 37 ◦C for 4 h.
igh-titre phage solution was removed from the plates, centrifuged
8000 × g, 10 min) to remove cell debris and then ﬁlter-sterilised
pore size, 0.22 m).  A polyethylene glycol (PEG) (Sigma-Aldrich)
uriﬁcation step was further added to remove any possible bacte-
ial debris from the suspensions. Brieﬂy, 10% (w/v) PEG (MW 8000)
as added to the lysate and left overnight at 4 ◦C. The next day,
he solution was centrifuged (4000 rpm, 30 min) to obtain a PEG-
phage pellet. The pellet was re-suspended gently in 1 mL  of SM
uffer and was vortexed thoroughly. The ﬁnal solutions were stored
t 4 ◦C. All of the necessary dilutions were performed in SM buffer.
or titration of the bacteriophage content in the haemolymph, a
imilar methodology to the propagation was followed. Several dilu-
ions were mixed with host bacterial cells and 3 mL  of soft agar was
dded and poured onto agar plates. Following overnight incubation,
laques were counted to determine the phage titre.
.3. Galleria mellonella phage therapy assayLarvae of G. mellonella were obtained from Livefood UK Ltd.
Rooks Bridge, UK). Larvae were stored at 4 ◦C and were used
ithin 1 week. A modiﬁed methodology developed by Peleg et al.timicrobial Agents 46 (2015) 196–200 197
was used to infect each G. mellonella [8]. Brieﬂy, G. mellonella
were surface-sterilised with a FASTAID pre-injection swab (Sigma-
Aldrich) containing 70% ethanol (Sigma-Aldrich). Using a pair of
tweezers, each G. mellonella was  restrained and, using a 26 G
Terumo syringe (VWR International, Lutterworth, UK), 10 L of
inoculum containing either 100 or 10 cells of P. aeruginosa was
delivered into the larval haemolymph behind the last proleg. For the
treatment model, phage suspension was delivered behind the last
proleg on the opposite side to the bacterial injection site 2 h post-
infection, and for the prevention experiment phage suspension was
given 2 h pre-infection. All experiments used 15 larvae per treat-
ment. A positive control group (larvae infected and treated with
PBS solution) and two  negative control groups (one group injected
with PBS only, assessing the impact of any negative effect from the
injection process; and one group injected with phage suspension
only, assessing toxicity of the phage cocktail) were also included.
Larvae were placed into Petri dishes and were incubated at 37 ◦C.
G. mellonella were examined hourly after 15 h post-infection and
were recorded as dead when they did not move in response to
touch.
2.4. Bleeding larval haemolymph
The prevention model was used to follow the kinetics of bacte-
ria and phage interactions within the larval haemolymph over time.
The phage cocktail, or PBS, was  administered 2 h prior to infection
and the phage titre was initially quantiﬁed within the haemolymph
at the time of infection (time zero). G. mellonella were infected
with 100 cells of P. aeruginosa PAO1 and at 8 h and 24 h three G.
mellonella were sacriﬁced and bled following incision made with
forceps to quantify phage and P. aeruginosa both in phage- and
PBS-treated G. mellonella.  Titrations of haemolymph were made in
SM buffer for phage counts. Quantiﬁcation of PAO1 was done by
preparing serial dilutions of haemolymph in 10 mM ferrous ammo-
nium sulfate (FAS) (Sigma-Aldrich) for inactivation of extracellular
phage. Bacteria were enumerated by total viable count of FAS dilu-
tions onto LB agar. Inactivation of phages by FAS was  conﬁrmed
prior to experimental procedure (data not shown). To rule out the
possibility of PAO1 evolving phage resistance during in vivo infec-
tion, re-isolated PAO1 were subjected to plaque assay to conﬁrm
susceptibility.
2.5. Statistical analysis
Kaplan–Meier survival curves and log-rank (Mantel–Cox) sta-
tistical test were performed using GraphPad Prism (GraphPad
Software Inc., La Jolla, CA).
3. Results
3.1. Treatment of infection
In this study, two models of phage and infection interactions
were examined. The ﬁrst was  a treatment whereby G. mellonella
was infected with either 10 or 100 cells of P. aeruginosa PAO1 and
left to allow an infection to establish for 2 h. Varying multiplicity
of infection (MOI) of phage were then administered and mortality
was observed over 48 h. No mortality was  recorded in the PBS con-
trols. However, G. mellonella treated with PBS died quicker when
infected with 100 cells compared with 10 cells. Administration of
phage, displaying lytic activity against PAO1 in vitro, prolonged the
survival of G. mellonella in a dose-dependent manner, but 0% sur-
vival was  eventually seen in all groups by 30 h (Fig. 1A and B). At
24 h there was 100% mortality in the infected and untreated G. mel-
lonella, but 40% survival for those infected with 10 cells and treated
with a MOI  of 10 compared with 20% survival in those infected with
198 M.L. Beeton et al. / International Journal of Antimicrobial Agents 46 (2015) 196–200
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00 cells at the same MOI  (Fig. 1A and B). A statistically signiﬁcant
ifference was seen between the survival curves as determined by
og-rank (Mantel–Cox) test (P < 0.0001).
.2. Prevention of infection
The second model examined the effect of prevention of infec-
ion whereby G. mellonella was given a prophylactic dose of phage
 h prior to infection with P. aeruginosa PAO1. Similarly to the treat-
ent experiment, G. mellonella infected with 100 cells died quicker
han those infected with 10 cells when given PBS 2 h before infec-
ion (Fig. 2A and B). At 24 h, survival ranged from 80% in G. mellonella
nfected with 100 cells and given a MOI  of 100 to 35% in those given a
OI  of 0.1 (Fig. 2A). Survival ranged from 90% to 60% in G. mellonella
nfected with 10 cells and given MOIs of 100 and 1, respectively
Fig. 2B). A statistically signiﬁcant difference was seen between
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the survival curves as determined by log-rank (Mantel–Cox) test
(P < 0.0001).
3.3. Kinetics of Pseudomonas aeruginosa infection and effect of
phage treatment
To understand the kinetics of a P. aeruginosa infection within G.
mellonella, larvae were infected with 100 cells using the preven-
tion model of infection. Bacteria and phage were quantiﬁed at set
time points by bleeding the haemolymph. Recovered volumes of
haemolymph ranged from 20 L to 40 L, but numbers were stan-
dardised upon analysis. No endogenous P. aeruginosa or phage with
lytic activity against P. aeruginosa PAO1 were detected in the unin-
fected controls. For G. mellonella that were given P. aeruginosa PAO1
only, the number of cells isolated from the haemolymph increased
over the duration of the experiment. By 24 h, all G. mellonella were
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ead and number of P. aeruginosa were in the order of 108 CFU/mL.
he second group of G. mellonella was given a prophylactic dose of
hage 2 h prior to infection and then phage and bacteria were quan-
iﬁed over the course of the infection. The number of P. aeruginosa
AO1 was comparable with that of the non-treated G. mellonella
fter 8 h of infection, but were three orders of magnitude less at
4 h compared with the non-treated G. mellonella.  These G. mel-
onella were alive at 24 h. The number of phages increased over the
uration of the infection, reaching a peak titre at 24 h of 108 PFU/mL.
.4. Low-passage clinical isolates of Pseudomonas aeruginosa
To validate the model of phage therapy with P. aeruginosa, we
ought to test the model with low-passage clinical strains isolated
rom patients with bacteraemia or CF (Fig. 4A and B). With the
A45291 bacteraemia strain, all infected G. mellonella were dead by
4 h, whereas there was 60% survival at 28 h in the group treated
ith phage at a MOI  of 10. When G. mellonella were infected with
he BC09007 CF strain there was little mortality at 24 h (90%) when
iven PBS as treatment, but there was 100% survival in the phage-
reated group. By 40 h, all G. mellonella were then dead.
. Discussion
To avoid a scenario whereby society is plunged back into a pre-
ntibiotic era, there is an urgent need to identify novel antibacterial
gents. Phage therapy offers a novel non-antibiotic approach to
elp in this battle. Phage therapy offers a different mode of action
ompared with antibiotics and therefore antibiotic-resistant orga-
isms can still be susceptible to phages. In addition, phages are
ighly selective and will therefore not wipe out the host microbiota,
nlike antibiotics, as well as being deemed safe in trials [9–11].
The G. mellonella infection model provides a system that can
ridge the gap between in vitro studies and more advanced mam-
alian studies, giving initial proof-of-principle data. Mammalian
odels are crucial for testing the efﬁcacy of phages prior to human
rials, but drawbacks include the need for sufﬁcient infrastructure,
ubstantial costs as well as the need for ethical approval. G. mel-
onella larvae have been used to examine numerous host–pathogen
nteractions ranging from studies of pathogenicity to antimicrobial
ctivity, with a small number of these examining the potential for
hage therapy [12–14].
The P. aeruginosa PAO1 strain proved to be highly virulent, with
nly 10 cells per G. mellonella required to result in mortality at 24 h.
his is a very low infective dose in this model, with organisms such
s Staphylococcus aureus requiring 105–106 cells/G. mellonella for
ortality, Acinetobacter baumannii requiring >104 and Helicobac-
er pylori requiring 106–107 cells for establishment of infection
15–17]. This low infectious dose is of particular interest as it
educes the chances of endotoxic shock due to rapid lysis of high
umbers of Gram-negative bacterial cells.
Two models of therapy were examined. The ﬁrst was  a treat-
ent methodology whereby an acute 2-h infection was allowed
o establish prior to administration of phage. At all MOIs of phage
here was prolonged survival of G. mellonella regardless of whether
0 or 100 bacterial cells were used as the inoculum. Although there
as increased survival compared with the control, there was a
ifference in survival depending on the number of cells in the inocu-
um. Presumably the 10-fold higher inoculum of 100 cells versus 10
ells meant that the infection had become more established within
he 2-h time frame therefore reducing the efﬁcacy of the phage to
rolong survival.
The second model examined the ability to prevent infection
sing prophylactic administration of phage 2 h prior to infec-
ion. When compared with the treatment model, prophylacticFig. 3. In vivo kinetics of Pseudomonas aeruginosa PAO1 infection within Galleria
mellonella with and without phage treatment. MOI, multiplicity of infection.
administration of phage resulted in greater survival after 24 h
at all comparable MOI  values. Presumably this increased efﬁcacy
was the result of phage being able to distribute throughout the
haemolymph over the 2-h period prior to infection, whereas in the
treatment model the bacteria will have had opportunity to estab-
lish and begin to express toxins. Interesting was the observation of
greater survival among G. mellonella that received the higher inocu-
lum of 100 cells compared with 10 cells. This may  have been due
to the higher number of bacterial cells, resulting in an increased
chance of bacteria and phage interaction resulting in a more rapid
ampliﬁcation of the phage.
In both models, phage-treated G. mellonella eventually suc-
cumbed to the infection, resulting in mortality by 30 h post-
infection. For this reason, we  explored the kinetics of both the
P. aeruginosa infection as well as the effect of phage on bacterial
numbers in vivo. The most striking observation was the compar-
ison between numbers of P. aeruginosa in the phage-treated and
untreated G. mellonella.  At 24 h the phage had kept the number of
P. aeruginosa to 1000-fold less than the non-treated G. mellonella,
but even in the presence of high titres of phage there had still been
active growth, and therefore infection, from P. aeruginosa over the
duration of the experiment. We  had previously hypothesised that
the reason for eventual mortality was the lack of available phage
for clearance. From Fig. 3 it is clear that this is not the case owing
to the high titre of phage within the haemolymph, although the
MOI  had shifted from 100 to <1 by 24 h. This hypothesis was also
ruled out by an experiment where G. mellonella was  given a second
dose of phage 4 h after an initial dosing, but there was  no difference
when compared with the single dose control (data not shown). One
possibility for the continual survival of PAO1 in the presence of a
high titre of phage was  the evolution of phage resistance within
the G. mellonella.  This was ruled out after observation of no bacterial
growth when co-cultivating P. aeruginosa single colonies, recovered
at 24 h after phage treatment, and a suspension of phage cocktail
(data not shown). The ﬁnal explanation for the survival could be
the intracellular localisation of P. aeruginosa.  In these experiments
only bacterial numbers within extracted haemolymph were exam-
ined. Pseudomonas aeruginosa is known to have the ability to invade
epithelial cells, which would protect from attack by the phage [18].
This highlights one of the limitations of phage therapy on pathogens
that are able to exist and replicate in an intracellular environment.
Perhaps combination therapy with antibiotics that can enter host
cells, such as a ﬂuoroquinolone or tetracycline, would have aided
in clearance, but this was  beyond the scope of this study. This
potential intracellular survival strategy would also explain why
the prevention model showed improved survival compared with
the treatment model, whereby the P. aeruginosa will have establish
within cells before the G. mellonella received a dose of the phage.
200 M.L. Beeton et al. / International Journal of Antimicrobial Agents 46 (2015) 196–200
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lthough we hypothesise that the lack of P. aeruginosa clearance
as due to intracellular localisation, there must have been a degree
f extracellular replication of cells within the haemolymph to allow
or the observed propagation of the phage over time.
Finally, we looked to demonstrate the effectiveness of the phage
odel on clinical isolates of P. aeruginosa.  To do this, the prevention
odel was repeated with clinical isolates from a bacteraemia and
 CF infection. Here the acute isolate resulted in rapid mortality of
he G. mellonella within 24 h, with 85% survival when given phage
t a MOI  of 10. Interestingly, the CF isolate was less virulent at 24 h
ompared with the bacteraemia and PAO1 strains, but 100% mor-
ality was then seen by 40 h. In conclusion, we present data for the
se of G. mellonella as a simple, robust and cost-effective model for
nitial examination of P. aeruginosa-targeted phage therapy.
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